Edition:
United States

People: Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

26.78USD
24 Mar 2017
Change (% chg)

$0.14 (+0.53%)
Prev Close
$26.64
Open
$26.49
Day's High
$27.00
Day's Low
$26.08
Volume
203,479
Avg. Vol
419,365
52-wk High
$41.69
52-wk Low
$23.07

McLaughlin, Kevin 

Mr. Kevin McLaughlin is Chief Financial Officer, Senior Vice President, Treasurer of Acceleron Pharma, Inc. He joined Acceleron in November 2010. Since January 2015, Mr. McLaughlin has served on the board of directors of Vericel Corporation. He also recently served, from 2009 through 2010, as Senior Vice President and Chief Financial Officer of Qteros, Inc. He was a co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company's initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the board of directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a BS in business from Northeastern University and an MBA from Babson College.

Basic Compensation

Total Annual Compensation, USD 353,275
Restricted Stock Awards, USD 1,243,600
Long-Term Incentive Plans, USD --
All Other, USD 1,159,530
Fiscal Year Total, USD 2,756,410

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 89,500 2,667,020.00
Name Fiscal Year Total

Francois Nader

284,962

Habib Dable

--

Kevin McLaughlin

2,756,410

Steven Ertel

4,278,920

Matthew Sherman

3,417,170

Ravindra Kumar

--
As Of  30 Dec 2015